- Home
- PKG vs BIIB Comparison
PKG vs BIIB Comparison
Compare PKG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKG
- BIIB
- Stock Information
- Founded
- PKG 1867
- BIIB 1978
- Country
- PKG United States
- BIIB United States
- Employees
- PKG N/A
- BIIB N/A
- Industry
- PKG Containers/Packaging
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PKG Consumer Discretionary
- BIIB Health Care
- Exchange
- PKG Nasdaq
- BIIB Nasdaq
- Market Cap
- PKG 19.6B
- BIIB 18.7B
- IPO Year
- PKG 2000
- BIIB 1991
- Fundamental
- Price
- PKG $212.09
- BIIB $144.87
- Analyst Decision
- PKG Buy
- BIIB Buy
- Analyst Count
- PKG 6
- BIIB 27
- Target Price
- PKG $225.17
- BIIB $188.09
- AVG Volume (30 Days)
- PKG 855.6K
- BIIB 1.5M
- Earning Date
- PKG 10-22-2025
- BIIB 10-29-2025
- Dividend Yield
- PKG 2.33%
- BIIB N/A
- EPS Growth
- PKG 25.72
- BIIB 31.67
- EPS
- PKG 10.02
- BIIB 10.45
- Revenue
- PKG $8,640,800,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- PKG $7.46
- BIIB $2.00
- Revenue Next Year
- PKG $8.20
- BIIB N/A
- P/E Ratio
- PKG $21.45
- BIIB $13.83
- Revenue Growth
- PKG 8.98
- BIIB 3.36
- 52 Week Low
- PKG $172.72
- BIIB $110.04
- 52 Week High
- PKG $250.82
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- PKG 53.24
- BIIB 60.19
- Support Level
- PKG $209.93
- BIIB $141.12
- Resistance Level
- PKG $217.51
- BIIB $147.23
- Average True Range (ATR)
- PKG 3.97
- BIIB 4.65
- MACD
- PKG -0.88
- BIIB 0.23
- Stochastic Oscillator
- PKG 20.81
- BIIB 71.16
About PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.